Alector Inc. (ALEC)
NASDAQ: ALECHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ALEC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $347.63M
- P/E (TTM)
- 6.31
- EPS (TTM)
- $0.37
- Dividend yield
- None
- 52-week range
- 1.09 – 2.84
- Day range
- 2.28 – 2.47
- Volume / Avg
- 1.95M / 3.34M
- Beta
- —
- Shares outstanding
- 148.88M
52-week range
ALEC stock today
On Nov 20, ALEC ended the session at $2.34, adding $0.035 (1.52%), versus the S&P 500's 3.70% decline. Shares are 17.8% below their 52-week high of $2.84, set on Nov 11, 2026 and 114.2% above the 52-week low of $1.09, in the middle of the past year's range. ALEC is up 49.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 88.3%.
Alector trades at 6.3x its trailing twelve-month earnings per share of $0.37.
Summary generated from market data by MetaCap's automated system. Methodology
About Alector
Company profileAlector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Arnon Rosenthal Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 103
- IPO year
- 2019
- Website
- alector.com
Financial highlights
Full financialsIn fiscal 2025, Alector generated $21.0 million in revenue, down 79.1% from fiscal 2024, its first annual decline since 2023. Alector reported a net loss of $142.9 million, compared with a loss of $119.0 million a year earlier. Operating margin was -741.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $21.05M | $100.56M | $97.10M | $133.60M | $207.09M |
| Growth | -79.07% | +3.56% | -27.32% | -35.49% | +881.54% |
| Net income | $-142.93M | $-119.05M | $-130.39M | $-133.31M | $-36.33M |
| EPS (diluted) | $-1.39 | $-1.23 | $-1.56 | $-1.62 | $-0.45 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$4.42+89.29%
- Strong buy 0
- Buy 4
- Hold 2
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $1.11 vs $-0.23
- Surprise
- +582.61%
ALEC news
All ALEC news- IQVIA Stock Jumps 59% in 6 Months: Here's What You Should KnowNasdaqIQV, ACHC, ALEC
- Are Medical Stocks Lagging Alector (ALEC) This Year?NasdaqALEC, CVS
- Alector Consensus Price Target Increased by 15.38% to $4.59Nasdaq
- Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineNasdaqMRNA, ALEC
- Alector Consensus Price Target Increased by 25.81% to $3.98Nasdaq
- Alector Announces Pricing of Underwritten OfferingGlobeNewswire
- Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineGlobeNewswire
- Novartis Halts Development Of VHB937 After ASTRALS Phase 2 Trial Fails To Meet EndpointNasdaqALEC, NVS
Alector peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CCCCC4 Therapeutics Inc. | 2.48 | +1.64% | $325.67M | vs ALEC |
| SLBTSL Science Holding Limited | 0.55 | -3.36% | $308.42M | vs ALEC |
| XFORX4 Pharmaceuticals Inc. | 3.00 | +1.35% | $306.34M | vs ALEC |
| TRXBTRex Bio Inc. | 10.32 | +6.12% | $296.95M | vs ALEC |
| CADLCandel Therapeutics Inc. | 5.04 | -1.75% | $395.37M | vs ALEC |
| DTILPrecision BioSciences Inc. | 7.40 | +7.09% | $282.46M | vs ALEC |
| TVGNTevogen Inc. | 5.90 | -6.35% | $405.20M | vs ALEC |
| TECXTectonic Therapeutic Inc. | 20.73 | -1.47% | $405.26M | vs ALEC |
Indexes, lists and sector
Alector stock FAQ
What is Alector's stock price today?
ALEC last traded at $2.34 as of Nov 20, 4:00 PM EST, up 1.52% on the day. Prices are delayed at least 15 minutes.
What is ALEC's P/E ratio?
ALEC trades at a trailing P/E ratio of 6.31.
Who is Alector's CEO?
Dr. Arnon Rosenthal Ph.D. is the chief executive officer of Alector Inc., which has about 103 employees.
What is the ALEC 52-week high?
The 52-week high for ALEC is $2.84 and the 52-week low is $1.09. The stock is currently 17.8% below its high.